BENSALEM, Pa.--(BUSINESS WIRE)--Law Offices of Howard G. Smith announces an investigation on behalf of investors in HeartWare International, Inc. (“HeartWare” or the “Company”) (NASDAQ:HTWR) securities. The investigation focuses on whether the Company and its officers violated securities laws by issuing misleading information to investors related to the Company’s MVAD clinical trials. HeartWare investors with losses of over $50,000 are encouraged to contact Howard G. Smith, Esq. to discuss their legal claims.
On September 9, 2015, the Company reported that it had, “paused its MVAD clinical trial to address an MVAD controller manufacturing process issue.” Then on September 13, 2015, the Company reported certain adverse events in clinical trials of the Company’s MVAD products, and stated that the MVAD clinical trials may not be re-initiated. On this news shares of HeartWare declined sharply in value, falling $7.61 per share, or over 17%, during intra-day trading on October 13, 2015.
If you purchased or otherwise acquired HeartWare securities and have suffered a loss, or if you have information or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Howard G. Smith, Esquire, of Law Offices of Howard G. Smith, 3070 Bristol Pike, Suite 112, Bensalem, Pennsylvania 19020 by telephone at (215) 638-4847, toll-free at (888) 638-4847, or by email to howardsmith@howardsmithlaw.com, or visit our website at http://www.howardsmithlaw.com.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.